AVEN

Across TCGA pan-cancer cohorts, AVEN mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AVEN data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher AVEN mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AVEN expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where AVEN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.383	0.869	<.001	21	view →
CCRCC	DFS	Quartile	All	0.832	0.986	.024	10	view →
HNSC	OS	Quartile	All	0.756	0.916	.013	8	view →
UCEC	OS	Median	All	1.000	0.911	.015	6	view →
LUAD	DFS	Quartile	All	0.996	0.782	.016	6	view →
GBM	OS	Tertile	All	0.607	0.830	.027	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AVEN–PDAC (DFS)

Open the PDAC breakdown →